Literature DB >> 16393297

Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.

V Khoshoo1, C Armstead, L Landry.   

Abstract

AIM: To determine the effect of a laxative alone and in combination with tegaserod in alleviating pain and improving stool frequency in adolescents with constipation predominant irritable bowel syndrome. PATIENTS: Forty-eight postpubertal adolescents of both sexes with constipation predominant irritable bowel syndrome, as defined by Rome II criteria, were randomly allocated to Group A (n = 27) for treatment with a laxative (polyethylene glycol 3350 oral solution) only or Group B (n = 21) for combination therapy with the laxative and tegaserod. Symptoms of abdominal pain (scale 0-10) and frequency of bowel movements were recorded daily in the pre-treatment phase and the post-treatment phase after a 7-day 'washout' period. Patients served as their own controls.
RESULTS: Treatment with the laxative alone (Group A) resulted in significant increase in frequency of bowel movements (P < 0.05), but not significant improvement in pain (P > 0.05). Treatment with the combination of the laxative and tegaserod (Group B) led to significant increase in the frequency of bowel movements and also significant reduction in pain (P < 0.05).
CONCLUSIONS: The laxative alone improved stooling but not pain in adolescents with constipation predominant irritable bowel syndrome. Addition of tegaserod resulted in alleviation of pain as well.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393297     DOI: 10.1111/j.1365-2036.2006.02705.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  29 in total

1.  Irritable bowel syndrome--the main recommendations.

Authors:  Viola Andresen; Jutta Keller; Christian Pehl; Michael Schemann; Jan Preiss; Peter Layer
Journal:  Dtsch Arztebl Int       Date:  2011-11-04       Impact factor: 5.594

Review 2.  Diagnosis and management of IBS.

Authors:  Sarah Khan; Lin Chang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10       Impact factor: 46.802

3.  The treatment of irritable bowel syndrome.

Authors:  Brian E Lacy; Kirsten Weiser; Ryan De Lee
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

4.  Treatment options for chronic abdominal pain in children and adolescents.

Authors:  Adrian Miranda; Manu Sood
Journal:  Curr Treat Options Gastroenterol       Date:  2006-09

Review 5.  Pharmacological interventions for recurrent abdominal pain in childhood.

Authors:  Alice E Martin; Tamsin V Newlove-Delgado; Rebecca A Abbott; Alison Bethel; Joanna Thompson-Coon; Rebecca Whear; Stuart Logan
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

Review 6.  Current and emerging pharmacotherapeutic options for irritable bowel syndrome.

Authors:  Jose L Barboza; Nicholas J Talley; Baharak Moshiree
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

7.  Understanding and Managing IBS and CIC in the Primary Care Setting.

Authors:  Brooks D Cash
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

8.  SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada.

Authors:  William D Chey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-02

9.  Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome.

Authors:  Tisha N Lunsford; Lucinda A Harris
Journal:  Int J Womens Health       Date:  2010-10-27

Review 10.  Measuring the symptoms of pediatric constipation and irritable bowel syndrome with constipation: expert commentary and literature review.

Authors:  Robert A Arbuckle; Robyn T Carson; Linda Abetz-Webb; Jeffrey Hyams; Carlo Di Lorenzo; Barbara E Lewis; Elizabeth Gargon; Caroline Kurtz; Steven J Shiff; Jeffrey M Johnston
Journal:  Patient       Date:  2014       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.